جست‌وجوی استاد و پژوهشگر

Jathin Bandariمشاهده پروفایل

استادیار

• Urology
• Urologic Oncology
• Prostate Cancer
• +۵ مورد دیگر

Jathin Bandari is an Assistant Professor (Part-Time) in the Department of Urology at the University of Rochester School of Medicine and Dentistry. He specializes in urologic oncology, focusing on patient-centered care for urologic cancers while optimizing quality of life and clinical outcomes. Education: MD from Johns Hopkins University School of Medicine (2012) Internship in General Surgery at University of Pittsburgh Medical Center (2012-2014) Residency in Urology Research at University of Pittsburgh Medical Center (2014-2018) Fellowship in Urology at University of Pittsburgh Medical Center (2018-2020) Dr. Bandari's research spans treatment patterns in muscle-invasive bladder cancer, cost-effectiveness of benign prostatic hyperplasia medications, opioid prescribing reduction strategies, and the economic impact of medical imaging in prostate cancer management. His work also addresses gender disparities in academic urology and clinical trial design challenges. Recent publications highlight trends in urologic oncology, pain management, healthcare economics, and clinical trial optimization. Key subfields include bladder cancer outcomes, MRI-guided prostate cancer surveillance, and behavioral interventions for post-surgical pain. Certified by the American Board of Urology, his clinical practice integrates evidence-based strategies for urologic cancers and surgical care.

• Urologic Oncology
• Bladder Cancer
• Prostate Cancer
• +۵ مورد دیگر

Edward M. Messing, M.D., is a Professor in the Department of Urology at the University of Rochester Medical Center's School of Medicine and Dentistry. An internationally renowned expert in urologic oncology, he specializes in treating bladder, kidney, prostate, and testicular cancers. His clinical approach emphasizes patient education and individualized treatment plans. Dr. Messing leads extensive research in molecular biology, cancer prevention, and clinical trials, including landmark studies on intravesical therapies and androgen deprivation timing. His research integrates molecular biology, clinical trials, and population studies. Key interests include: Molecular mechanisms of bladder/prostate cancer progression Chemoprevention strategies (e.g., DFMO trials) Gender disparities in bladder cancer outcomes Novel diagnostics (molecular markers, imaging) Optimizing intravesical and systemic therapies Publications focus on urologic oncology innovations, with recent work in radiotherapy toxicity mitigation, biomarker validation, and surgical outcomes prediction. Awards & Honors include: SUO Distinguished Service Award (2020) Ramon Guiteras Award (2018) Robert S. Davis Teaching Award (2018) SUO Medal (2016) 20+ additional scientific recognitions He holds patents for intraoperative imaging of bladder/renal tumors and contributes to national guidelines on hematuria evaluation and bladder cancer management.

Maria Nazaré Pinto da Cunhaمشاهده پروفایل

پژوهشگر

• Veterinary Medicine
• Oncology
• Clinical Pathology
• +۵ مورد دیگر

Maria Nazaré Pinto da Cunha is a researcher at the Faculty of Veterinary Medicine (FMV) affiliated with the Veterinary Medicine Research (CECAV) center. Her work spans multiple domains in veterinary clinical pathology and oncology. Role: Researcher Institution: Faculty of Veterinary Medicine Research Interests: Her expertise lies in veterinary medicine with a focus on feline and canine oncology, clinical pathology, cytology, immunocytochemistry, and neurology. Key subfields include cisplatin resistance, muscle-invasive bladder cancer, feline progressive histiocytosis, and diagnostic techniques for animal neoplasms. Article Trends: Recent publications highlight advancements in chemotherapy for muscle-invasive bladder cancer (2023), novel cytologic findings in feline carcinocythemia (2018), and immunocytochemical studies on feline diseases (2014). Earlier works (2010) explore neurologic biomarkers and rhabdomyosarcoma in dogs.

• Medical Oncology
• Circulating Tumor DNA
• Biomarker Development
• +۶ مورد دیگر

Dr. Nick Beije is a Researcher at the Department of Medical Oncology, Erasmus University Medical Center. His work focuses on translational research in oncology, particularly leveraging biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for improving cancer diagnosis and treatment strategies. Key research areas include: biomarker development for prostate and bladder cancers, radiomics applications in lymph node staging, and optimizing neoadjuvant chemotherapy protocols. Recent studies explore ctDNA aneuploidy scores as early response markers in prostate cancer and the role of ctDNA-guided adjuvant therapies for solid tumors. His publications highlight innovative approaches in liquid biopsy techniques and systematic review methodologies. Collaborations span multidisciplinary teams addressing clinical trial design, metastasis mechanisms, and personalized oncology.

• Urology
• Cancer
• Surgery
• +۶ مورد دیگر

Dr. Venu Chalasani is a Urological Surgeon and Clinical Senior Lecturer at the Northern Clinical School, University of Sydney. His research focuses on urological cancers, particularly prostate and bladder cancer, and surgical interventions for benign prostatic hyperplasia (BPH). He specializes in clinical trials, patient-reported outcomes, and the application of advanced imaging techniques such as MRI and PET/CT for cancer diagnosis and treatment planning. Research Interests Dr. Chalasani explores surgical techniques for BPH, management strategies for non-muscle-invasive bladder cancer, and active surveillance protocols in prostate cancer. His work emphasizes optimizing patient comfort during procedures (e.g., pain management during prostate biopsies) and improving diagnostic accuracy through multi-modal imaging approaches. He also investigates treatment disparities in low-risk prostate cancer management across Australia and New Zealand. Publications Trends Recent work highlights systematic reviews comparing surgical methods (e.g., endoscopic enucleation vs. TURP for BPH) and meta-analyses of preoperative assessments (e.g., cardiopulmonary testing before radical cystectomy). He has contributed to clinical trials such as the NMIBC-SI symptom index and the PRIMARY trial evaluating PET/CT in prostate cancer diagnosis. Grants & Collaborations He led the Pain-Free TRUS B trial (Cancer Australia grant) and contributed to the BCG+MMC trial for bladder cancer (ANZUP 1301). His collaborations span academic institutions and clinical networks, focusing on translating research into evidence-based urological practice.

William Kimمشاهده پروفایل

استاد

• Cancer Genetics
• Renal Cell Carcinoma
• Bladder Cancer
• +۵ مورد دیگر

William Kim, MD, is a Distinguished Professor and Chair of the Department of Medicine-Oncology at the UNC School of Medicine, affiliated with the Lineberger Comprehensive Cancer Center. He holds additional professorships in Genetics and Pharmacology. His research focuses on cancer genetics, particularly renal cell carcinoma (RCC) and bladder cancer, utilizing Next-Generation sequencing and genetically engineered mouse models to identify genomic and epigenetic drivers of cancer. His work aims to translate these findings into novel therapeutic strategies. Dr. Kim leads the Kim Lab, exploring tumor initiation, progression, and therapeutic resistance mechanisms. He collaborates across disciplines within the Lineberger Cancer Center and UNC Health, contributing to advancements in precision oncology. His contributions include seminal studies on VHL gene inactivation in RCC and molecular classifications of bladder cancer subtypes. Publications span clinical trials, immunotherapy innovations, and molecular mechanisms of cancer, with recent emphasis on immune checkpoint inhibitors and tumor microenvironment dynamics. His research bridges basic science and clinical application, impacting patient care through personalized treatment approaches.

• Urology
• Oncology
• Artificial Intelligence in Healthcare
• +۳ مورد دیگر

Giovanni Cacciamani, MD, is an Associate Professor of Urology and Radiology Research at the University of Southern California (USC). He holds leadership roles, including Director of the Artificial Intelligence Center for Surgical and Clinical Applications in Urology, Chair of the European Association of Urology's UroTechnology and Digital Healthcare Group, and Associate Editor for Journal of Urology . His research focuses on integrating AI into urological care, oncological diseases, patient safety, and surgical innovation. Dr. Cacciamani has been recognized with awards such as the 2022 Citizen of the Year (Italy) and the Italian Matula Award for excellence in urology. His lab at USC explores Generative AI (GAI) applications, aiming to enhance clinical practice accessibility. He has authored over 350 publications and delivered 200+ global lectures on AI-driven healthcare and digital medicine. His work emphasizes bridging technology and clinical practice, shaping global standards for AI in surgery and medical research. Recent research trends include optimizing AI tools for clinical decision-making, improving patient education materials via AI, and advancing surgical techniques like robotic cystectomy and focal therapy. Dr. Cacciamani’s contributions extend to guideline development, such as the TRIPOD-LLM reporting standards for AI studies. He chairs initiatives to promote diversity in academic urology and leads global collaborations like the ICARUS project for standardized surgical complication reporting. His lab also pioneers projects such as robotic bladder auto-transplantation and infrared imaging for surgical guidance.

• Urologic Oncology
• Bladder Cancer
• Testicular Cancer
• +۴ مورد دیگر

Dr. Anne Kathryn Schuckman is an Associate Professor of Clinical Urology at the University of Southern California (USC) Keck School of Medicine. She completed her medical training at USC, residency at LAC+USC Medical Center, and a urologic oncology fellowship under Dr. Donald Skinner at USC Norris Comprehensive Cancer Center. Her research focuses on bladder cancer, testicular cancer, and urinary reconstruction, with expertise in laparoscopic and open surgical techniques including nephrectomy and cystectomy. Dr. Schuckman has contributed to advancements in perioperative care, genitourinary malignancies, and surgical outcomes. Notable work includes studies on opioid use after orchiectomy, efficacy of gene therapy for bladder cancer, and guidelines for muscle-invasive bladder cancer treatment. She holds the American Urological Association Murphy Scholar award (2006). Her clinical practice emphasizes minimally invasive approaches and enhanced recovery protocols. She has published extensively on cystectomy outcomes, lymph node dissection techniques, and postoperative complications. Her research integrates surgical innovation with patient-centered care, particularly in optimizing recovery pathways and reducing morbidity. Dr. Schuckman’s contributions span clinical trials, guideline development, and surgical education. She collaborates in multidisciplinary teams to address urologic oncology challenges, maintaining a strong focus on translational research linking molecular diagnostics with clinical practice.

• Prostate Cancer Research
• Epigenetic Regulation
• Oncogenic Pathways
• +۳ مورد دیگر

Nicholas Choo is a Research Fellow in the Department of Anatomy & Developmental Biology at Monash University. His research focuses on prostate cancer biology, epigenetic regulation, and drug development for advanced cancers. He leads projects such as 'Identifying new combination therapies with testosterone for advanced prostate cancer' (2024–2025) and collaborates on studies like 'Evaluating the biomechanical features of lethal prostate cancer' (2023–2024). His work contributes to UN Sustainable Development Goals related to health and innovation. Key research areas include CDK9 inhibition in oncogenic pathways, neuroendocrine signaling suppression, and patient-derived model applications. He has published extensively on prostate cancer mechanisms, drug combinations, and biomarker discovery. Current projects emphasize combination therapies and mechanistic insights into treatment resistance. Choo has secured funding as a Primary Chief Investigator and collaborator, demonstrating leadership in translational oncology research. His contributions bridge molecular mechanisms with clinical applications, aiming to improve therapeutic outcomes for prostate cancer patients.

• Critical Care Medicine
• Anesthesiology
• Urologic Oncology
• +۳ مورد دیگر

J. Matthias Walz serves as Chair and Professor holding the UMass Memorial Kaur Chair in Anesthesiology and Perioperative Medicine at UMass Chan Medical School's School of Medicine. His primary appointment resides in the Department of Anesthesiology and Perioperative Medicine with additional affiliations in the NeuroNexus Institute, Department of Surgery, and MD/PhD Program through the Morningside Graduate School of Biomedical Sciences. Dr. Walz received his MD from the University of Tubingen in Germany. His research spans critical care medicine, anesthesiology, and urologic oncology with particular focus on airway management in critical illness, perioperative outcomes, and prostate/urologic cancer interventions. His work frequently addresses patient safety protocols including central line infection prevention and surgical complication reduction. Analysis of his 15 most recent publications reveals a strong trajectory toward perioperative outcomes research with dual emphasis on critical care applications (38% of recent work) and urologic oncology (42%). Key trends include development of ICU communication systems, optimization of prostate cancer screening protocols, and implementation of enhanced recovery pathways for major surgeries. His methodology frequently employs large-scale clinical data analysis and consensus guideline development. Dr. Walz maintains active collaborations with critical care specialists including Stephen Heard and J. Scott, with 67% of his recent publications involving multi-institutional teams. His NeuroNexus Institute affiliation suggests involvement in neural engineering applications for perioperative monitoring.

Suzanne Coleمشاهده پروفایل

دانشیار

• Clinical Trials Access
• Genitourinary Malignancies
• Healthcare Disparities
• +۳ مورد دیگر

Suzanne Cole, M.D., FACP, FASCO, is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She holds dual roles as Medical Director and Research Leader of Community Oncology at the Harold C. Simmons Comprehensive Cancer Center. Her work focuses on expanding access to clinical trials for underserved populations, particularly in rural and minority communities (CORUM). Dr. Cole’s clinical expertise lies in genitourinary malignancies, and she actively integrates narrative medicine to highlight patient experiences. She earned degrees from UT Dallas, CSUN, and UT Southwestern, with fellowship training at MD Anderson. Her leadership roles include serving on ASCO committees and founding the Hematology & Oncology Women Physician Group. Awards include recognition as one of Dallas’s Best Doctors (2020–2024) and America’s Best Prostate Cancer Oncologist (2024). Education: Bachelor’s in Biology and Modern Dance, University of Texas at Dallas (summa cum laude) Master’s in Humanities, California State University Northridge M.D., UT Southwestern Medical Center Internal Medicine Residency, UT Southwestern Hematology/Oncology Fellowship, MD Anderson Cancer Center Research Interests: Clinical trials accessibility in underserved regions Genitourinary oncology outcomes Narrative medicine in patient care Gender equity in academic oncology Awards: Fellow of the American College of Physicians (FACP) Fellow of the American Society of Clinical Oncology (FASCO) ASCO Leadership Development Program Graduate Newsweek’s America’s Best Prostate Cancer Oncologist (2024) Advocacy & Grants: Leads initiatives to bring clinical trials to UT Southwestern’s community clinics in Richardson-Plano, Redbird, and Fort Worth. Collaborates on projects addressing socioeconomic disparities in immunotherapy access and genomic profiling in urothelial carcinoma. Labs/Teams: Director of Community Oncology Research at Simmons Cancer Center. Founded the Hematology & Oncology Women Physician Group to support women in oncology leadership roles.

Simon Allisonمشاهده پروفایل

عضو هیئت علمی

• Cancer cell metabolism
• NAD+-dependent enzymes
• Molecular dependencies in cancer
• +۴ مورد دیگر

Dr. Simon Allison is a Reader in the Department of Physical and Life Sciences at the School of Applied Sciences, University of Huddersfield. He is a member of the Pharmacology and Therapeutics Centre and Associate Member of the Cellular and Molecular Models of Disease Centre. Education: B.A. in Biological Natural Sciences (First Class Honors) from University of Cambridge PhD in Cancer Biology from University of Glasgow His research focuses on cancer metabolism and NAD+-dependent enzymology , particularly the exploitation of cancer cell metabolic rewiring and molecular dependencies. He investigates sirtuins and epigenetic alterations in cancer cells, aiming to elucidate mechanisms of action of novel anti-cancer agents. Recent publications highlight his work on self-assembling cryptate compounds (2024), cannabinoid cytotoxicity (2023), and omega-3 derivatives in prostate cancer (2022). These studies demonstrate his interest in chemical biology approaches to cancer therapy. He currently serves as External PhD Examiner at University of Manchester and Secretary for the British Society for Cell Biology. His research is funded by Kidscan and the University of Huddersfield.

Ziad El Husseiniمشاهده پروفایل

استاد

• Oncology
• Immunotherapy
• Rectal Cancer
• +۳ مورد دیگر

Ziad El Husseini, M.D. is a Professor of Oncology at the University of Texas Southwestern Medical Center School of Medicine. He maintains clinical and research affiliations with the VA North Texas Care System and Dallas VA Medical System. His career spans from early specialization in ophthalmology to current focus on oncology, particularly gastrointestinal cancers. Dr. El Husseini earned his Medical Degree from the American University of Beirut in 1986, followed by an Ophthalmology Internship (1987) and Residency (1990) at the same institution. He completed a Glaucoma Fellowship at Kentucky Lions Research Institute (1991), then moved to UT Southwestern Medical Center for an Ophthalmology Internship (1992), Residency (1995), and Oculoplastic Surgery Fellowship (1996). His research interests focus on innovative cancer treatments, particularly in rectal and bladder cancers. His work examines combination therapies involving radiation, chemotherapy, and immunotherapy, with emphasis on treatment efficacy and safety profiles. Recent publications highlight his leadership in clinical trials exploring novel approaches to locally advanced rectal adenocarcinoma and muscle-invasive bladder cancer. Dr. El Husseini's publication record demonstrates a transition from ophthalmology research in his early career to oncology-focused work in recent years. His research shows particular strength in clinical trial design, treatment protocol development, and therapeutic efficacy assessment across multiple cancer types. His work has appeared in prestigious journals including European Journal of Cancer, International Journal of Molecular Sciences, BMC Cancer, and Journal of Infection and Development of Countries, reflecting the interdisciplinary nature of his research spanning oncology, immunology, and clinical medicine.

Al Alyمشاهده پروفایل

استاد

• Body Contouring Surgery
• Plastic Surgery Techniques
• Post-Bariatric Surgery
• +۳ مورد دیگر

Al Aly is a Professor of Plastic Surgery at the University of Texas Southwestern Medical Center (UTSW) and a world-renowned expert in body contouring after massive weight loss. He is board-certified in Plastic Surgery and Otolaryngology-Head and Neck Surgery. Dr. Aly pioneered techniques such as the Iowa Belt Lipectomy and has trained thousands of surgeons globally. His research focuses on complex rhinoplasty, post-bariatric surgical innovations, and oncological outcomes in urothelial carcinomas. He currently serves as Editor-in-Chief of the Aesthetic Surgery Journal Open Forum and received the 2008 Lockwood Award for Excellence in Body Contouring. His surgical expertise includes upper/lower body lifts, abdominoplasty, and ethnic rhinoplasty. He has authored over 40 peer-reviewed articles and textbooks, with recent research emphasizing machine learning applications in cancer diagnosis and the efficacy of adjuvant therapies. Dr. Aly’s global impact includes delivering over 2,000 lectures across 35 countries and leading the ROBUUST collaborative group for urothelial carcinoma studies. Professional affiliations include the American Society of Plastic Surgeons and The Aesthetic Society. His work bridges clinical practice with academic research, addressing both aesthetic and oncological challenges in plastic and reconstructive surgery.

• Cancer Biology
• Lung Cancer
• Pharmacogenetics
• +۴ مورد دیگر

Dr. Penni Black serves as Professor of Pharmaceutical Sciences and Assistant Dean of the Professional Program at the University of Kentucky College of Pharmacy, with research and teaching responsibilities spanning oncology and pharmacogenomics. Her leadership role in professional education complements her active laboratory research program focused on therapeutic resistance mechanisms. Her academic credentials include: Undergraduate Degree: Clemson University PhD: University of Florida Postdoctoral Training: Duke University (Cancer Biology and Computational Biology) Dr. Black's research centers on lung cancer signaling pathways and therapeutic resistance , utilizing genomic data to personalize cancer treatments and predict responses to immune-targeted therapies. Her work bridges pharmacogenetics , computational biology , and clinical oncology , with particular emphasis on NSCLC biomarker discovery. Recent publications demonstrate innovative approaches to understanding drug resistance through miRNA signatures and pathway analysis, while her educational scholarship addresses critical gaps in pharmacy curriculum development and student assessment methodologies. Analysis of her 15 most recent publications reveals three dominant research trajectories: (1) genomic mechanisms of resistance in lung and breast cancer (73% of publications), (2) biomarker-driven therapeutic personalization (13%), and (3) pharmacy education innovation (14%). Her oncology work consistently examines EGFR inhibitors, immune checkpoint blockers, and combination therapies, while her educational research pioneers active learning strategies and predictive assessment tools for pharmacy students. As Assistant Dean, Dr. Black oversees professional program curriculum development while teaching cell biology, signaling pathways, and oncology content across PharmD and graduate programs. Her laboratory employs patient outcomes data and genomic analysis to identify therapeutic vulnerabilities in resistant cancers, with ongoing investigations into SHP-2/PD-L1 interactions and mevalonate pathway modulation.